Stay updated with breaking news from Nrx Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NRx Pharmaceuticals, Inc. (NRXP) has signed a License Data and Technical Information Agreement with Columbia University for rights to data from a randomized, active-controlled trial of 80 patients hospitalized for Acute Suicidality in Depression.
Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enrollment of the originally-targeted...
FDA-compliant manufacture of intravenous Ketamine is a required component of a New Drug ApplicationIntravenous Ketamine has become widely used for treating depression and suicidality but has never...
Previously announced data sharing agreement for intravenous ketamine Newly available data highlight the need for a labeled form of IV ketamine that can qualify...
RADNOR, Pa., Oct. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chief Scientist of NRx Pharmaceuticals,...